G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2023

Description

“G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on g-csf (granulocyte colony stimulating factors) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for g-csf (granulocyte colony stimulating factors) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The g-csf (granulocyte colony stimulating factors) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Lenograstim (Granocyte); Filgrastim (Neupogen, Zarzio, Nivestim, Accofil); Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco); Lipegfilgrastim (Lonquex)

2) By Application: Oncological Diseases; Blood Disorders; Growth Hormone Deficiencies; Chronic And Autoimmune Disorders; Other Applications

3) By Product: Tablet; Capsule; Other Products

Companies Mentioned: BioCad; Teva Pharmaceuticals; Pfizer; Intas Pharmaceuticals; Novartis AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the G-CSF (Granulocyte Colony Stimulating Factors) market are: BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, StadaArzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories and Celltrion Inc.

The global G-CSF (granulocyte colony-stimulating factors) market is expected to grow from $7.37 billion in 2021 to $7.99 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The G-CSF (Granulocyte Colony Stimulating Factors) market is expected to reach $9.48 billion in 2026 at a CAGR of 4.4%.

The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

G-CSF (Granulocyte Colony Stimulating Factors) refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumours, neutropenia brought on by some types of chemotherapy, and severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.

The main types of G-CSF are lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco) and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablet, capsule, and others and is used in oncological diseases, blood disorders, growth hormone deficiencies, and chronic and autoimmune disorders, among others.

The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in December 2020, according to the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency that publishes research and data on cancer, it is anticipated that 28.4 million new cases of cancer will be diagnosed worldwide in 2040, up 47% over the anticipated 19.3 million cases in 2020, primarily due to population growth and aging. G-CSF is a class of growth factors that produce white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF market.

The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is another key factor driving the growth of the granulocyte-colony stimulating factor market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the granulocyte-colony stimulating factor market.

The high cost is a key factor limiting the growth of the G-CSF market. Improved chemotherapy administration is responsible for the rise in instant medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the costs of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (Granulocyte Colony Stimulating Factors) market.

In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, G-CSF baseddrugs would be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of biosimilars for the treatment of eye related diseases.

The regions covered in the G-CSF (Granulocyte Colony Stimulating Factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the G-CSF (Granulocyte Colony Stimulating Factors) market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market size, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (Granulocyte Colony Stimulating Factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2067

1. Executive Summary

2. G-CSF (Granulocyte Colony Stimutating Factors) Market Characteristics

3. G-CSF (Granulocyte Colony Stimutating Factors) Market Trends And Strategies

4. G-CSF (Granulocyte Colony Stimutating Factors) Market - Macro Economic Scenario

4.1 COVID-19 Impact On G-CSF (Granulocyte Colony Stimutating Factors) Market

4.2 Ukraine-Russia War Impact On G-CSF (Granulocyte Colony Stimutating Factors) Market

4.3 Impact Of High Inflation On G-CSF (Granulocyte Colony Stimutating Factors) Market

5. G-CSF (Granulocyte Colony Stimutating Factors) Market Size And Growth

5.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. G-CSF (Granulocyte Colony Stimutating Factors) Market Segmentation

6.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Accofil)
Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)
Lipegfilgrastim (Lonquex)
6.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Oncological Diseases
Blood Disorders
Growth Hormone Deficiencies
Chronic and Autoimmune Disorders
Others
6.3. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Tablet
Capsule
Others

7. G-CSF (Granulocyte Colony Stimutating Factors) Market Regional And Country Analysis

7.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market

8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China G-CSF (Granulocyte Colony Stimutating Factors) Market

9.1. China G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
9.2. China G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India G-CSF (Granulocyte Colony Stimutating Factors) Market

10.1. India G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market

11.1. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market

12.1. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market

13.1. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market

14.1. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market

15.1. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
15.2. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK G-CSF (Granulocyte Colony Stimutating Factors) Market

16.1. UK G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market

17.1. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France G-CSF (Granulocyte Colony Stimutating Factors) Market

18.1. France G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market

19.1. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
19.2. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market

20.1. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America G-CSF (Granulocyte Colony Stimutating Factors) Market

21.1. North America G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
21.2. North America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA G-CSF (Granulocyte Colony Stimutating Factors) Market

22.1. USA G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
22.2. USA G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America G-CSF (Granulocyte Colony Stimutating Factors) Market

23.1. South America G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
23.2. South America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market

24.1. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market

25.1. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
25.2. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market

26.1. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market Overview
26.2. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. G-CSF (Granulocyte Colony Stimutating Factors) Market Competitive Landscape And Company Profiles

27.1. G-CSF (Granulocyte Colony Stimutating Factors) Market Competitive Landscape
27.2. G-CSF (Granulocyte Colony Stimutating Factors) Market Company Profiles
- 27.2.1. BioCad
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. Teva Pharmaceuticals
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Pfizer
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. Intas Pharmaceuticals
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. Novartis AG
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. G-CSF (Granulocyte Colony Stimutating Factors) Pipeline Analysis

29. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimutating Factors) Market

30. G-CSF (Granulocyte Colony Stimutating Factors) Market Future Outlook and Potential Analysis

31. Appendix

31.1. Abbreviations
31.2. Currencies
31.3. Historic And Forecast Inflation Rates
31.4. Research Inquiries
31.5. The Business Research Company
31.6. Copyright And Disclaimer